en · de · es · fr · pt
selank-notes.peptides1126.com › Guide › Mechanism And Evidence Status — Beginner to Advanced

Mechanism And Evidence Status — Beginner to Advanced

By Editorial Desk · published 2026-02-23 · last reviewed 2026-04-06 · Guide

Tuftsin analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-04-06 and is reviewed periodically as new material appears.

Mechanism and Evidence Status

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Storage, Analysis, and Regulatory Status

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.

Selank at a glance

PropertyValueNotes
Primary route studiedIntranasalAlso examined parenterally in animal work
Reported plasma half-lifeMinutes to tens of minutesValues vary widely between reports
Main model systemsRodent behavioural and cell assaysHuman trials are few and small
Principal proposed targetsGABA-A receptor, GABA transaminaseMonoamine and neurotrophic pathways also reported
Evidence gradePreliminaryLimited independent replication

Stability, Handling, and Analytical Control

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.

Related pages on this site

Background and Peptide Identity

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Mechanism and Evidence Base

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Further detail

== History == Nefazodone was discovered by scientists at Bristol-Myers Squibb (BMS) who were seeking to improve on trazodone by reducing its sedating qualities. BMS obtained marketing approvals for nefazodone worldwide, including in the United States and Europe, in 1994. It was marketed in the United States under the brand name Serzone and in Europe under the brand name Dutonin. The first reports of serious liver toxicity with nefazodone were published in 1998 and 1999. These instances were quickly followed by many additional cases. In 2002, the United States Food and Drug Administration (FDA) obligated BMS to add a black box warning about potential fatal liver toxicity to the drug label. Worldwide sales in 2002 were $409 million. In 2003 Public Citizen filed a citizen petition asking the FDA to withdraw the marketing authorization in the United States, and in early 2004 the organization sued the FDA to attempt to force withdrawal of the drug. The FDA issued a response to the petition in June 2004 and filed a motion to dismiss, and Public Citizen withdrew the suit. Sales of nefazodone were about $100 million in 2003. By that time, it was also being marketed under the additional brand names Serzonil, Nefadar, and Rulivan. Generic versions were introduced in the United States in 2003 and Health Canada withdrew the marketing authorization that same year. In April 2004, BMS announced that it was going to discontinue the sale of Serzone in the United States in June 2004 and said that this was due to declining sales and generic versions being available in the United States.

=== Medicaid and illegal immigrants === The bill prompted claims that illegal immigrants receive Medicaid. Illegal immigrants are already ineligible for full Medicaid benefits under the Personal Responsibility and Work Opportunity Act, so many illegal immigrants access state-funded health programs instead. According to a CBO analysis, the bill's provisions could lead some states to cut back those state-funded health programs, potentially causing an estimated 1.4 million people to lose state-level health coverage, including illegal immigrants.

==== Orinoco River exploration ==== Humboldt’s expedition to the Upper Orinoco and the Casiquiare canal began at 4 a.m. on March 30, 1800, departing from San Fernando de Apure. The transition from the dry Llanos to the river marked a significant environmental change. The team, which included Don Nicolas Sotto, four Native rowers, and a pilot, traveled in a large sailing canoe outfitted with a cabin made of leaves and ox-hide benches. The river’s dense forests replaced the open horizons of the plains, and travel became more constrained. Wildlife was abundant, with numerous birds, capybaras, river dolphins, tapirs, peccaries, and alligators observed along the riverbanks, as well as piranhas and stingrays in the water. Humboldt noted the intensity of insect life, particularly at midday.

=== Cancer therapy === Experimental studies indicate that macrophages can affect all therapeutic modalities, including surgery, chemotherapy, radiotherapy, immunotherapy and targeted therapy. Macrophages can influence treatment outcomes both positively and negatively. Macrophages can be protective in different ways: they can remove dead tumor cells (in a process called phagocytosis) following treatments that kill these cells; they can serve as drug depots for some anticancer drugs; they can also be activated by some therapies to promote antitumor immunity. Macrophages can also be deleterious in several ways: for example they can suppress various chemotherapies, radiotherapies and immunotherapies. Because macrophages can regulate tumor progression, therapeutic strategies to reduce the number of these cells, or to manipulate their phenotypes, are currently being tested in cancer patients. However, macrophages are also involved in antibody mediated cytotoxicity (ADCC) and this mechanism has been proposed to be important for certain cancer immunotherapy antibodies. Similarly, studies identified macrophages genetically engineered to express chimeric antigen receptors as promising therapeutic approach to lowering tumor burden.

== Control and detection == The use of bracken fern as human food is mainly a historical question. The rhizomes of these plants served as human food in Scotland during the First World War. In America (USA, Canada), Russia, China and Japan, fern is grown commercially for human use. The usual procedure that is performed before eating the plant is to pre-treat the fern with boiling water in the presence of different chemicals, such as sodium bicarbonate and wood ash, to degrade or inactivate ptaquiloside and other toxic agents. Nevertheless, some carcinogenic activity persists even after the treatment. As shown by Kamon and Hirayama, the risk of oesophageal cancer was increased approximately by 2.1 in men and 3.7 in women who regularly consume bracken in Japan. Recent researches have suggested that sulfur-containing amino acids can potentially be used under appropriate conditions as detoxifying agents for ptaquiloside and selenium supplementation can prevent as well as reverse the immunotoxic effects induced by ptaquiloside. Ptaquiloside in the aqueous extract of bracken can be detected using different instrumental methods: thin-layer chromatography–densitometry (TLC-densitometry), high-performance liquid chromatography (HPLC), gas chromatography–mass spectrometry (GCMS), and liquid chromatography–mass spectrometry (LC-MS).

Sources: en.wikipedia.org

Background from the literature

Pardee (1912), neurologist, husband of Abby Rockefeller Alfred Sturtevant (1912), geneticist, protege of Thomas Hunt Morgan and winner of the National Medal of Science James Chapin (1916), ornithologist; 17th president of The Explorers Club Seeley G. Mudd (1917), physician and philanthropist, former dean of Keck School of Medicine of USC Harold Alexander Abramson (1919), early advocate of Psychedelic therapy Augustus Braun Kinzel (1919), metallurgist and first president of the National Academy of Engineering William V. Silverberg (1919), founder of the American Academy of Psychoanalysis and Dynamic Psychiatry Sherman Fairchild* (1920), founder of Fairchild Aircraft, Fairchild Industries, Fairchild Camera and Instrument as well as Fairchild Semiconductor Francis Bitter (1925), physicist, inventor of Bitter electromagnets Howard Bruenn (1925), personal physician to Franklin D. Roosevelt Albert Charles Smith (1926), botanist, former director of the National Museum of Natural History and the Arnold Arboretum Konrad Lorenz* (1926), winner of the Nobel Prize in Physiology or Medicine Jerrold R. Zacharias (1926), nuclear physicist, professor at Massachusetts Institute of Technology Andrew Streitwieser (1927), chemist known for his contributions to physical organic chemistry Julian M. Sturtevant (1927), chemist at Yale University Raymond D.

=== Dressings === After a wound is irrigated, debrided, and, if possible, closed, it should be dressed appropriately. The goals of a wound dressing are to act as a barrier to the outside environment, facilitate wound healing, promote hemostasis, and act as a form of mechanical debridement during dressing changes. The ideal wound dressing maintains a moist environment to optimize wound healing but is also capable of absorbing excess fluid as to avoid skin maceration or bacterial growth. Several wound dressing options are available, each tailored to different kinds of wounds:

KEZAD Areas A and B, which make up approximately 410 sq km of the 550 sq km total area, are located between Abu Dhabi and Dubai, adjacent to Khalifa Port, a major deep-water container port in the UAE. It lies along the E11 Highway with future road links connecting to Al Ain, and is near three major airports: Zayed International Airport (35 km); Al Maktoum International Airport (52 km); and Dubai International Airport (85 km). Companies based in KEZAD have access to multimodal transport by sea, air and road, with seamless integration Etihad Rail network that will connect KEZAD directly to industrial and consumer hubs across the UAE and GCC.

=== Depigmentation === In cases of extensive vitiligo, the option to depigment the unaffected skin with topical medications, such as monobenzone, mequinol, or hydroquinone may be considered to even out skin tone. The removal of all the skin pigment with monobenzone is permanent and vigorous. Lifelong sun safety is required to avoid severe sunburn and melanomas. Depigmentation takes about a year to complete.

Some women complain of a "small penis" when the trim procedure is performed, owing to the un-addressed clitoral hood tissue and completely removed (amputated) labia minor. Most plastic surgeons do not perform this procedure, and instead favor the extended wedge approach, which is technically more demanding, but produces a more natural result and is able to create a natural and proportioned appearance to the vulva. Reconstructive procedures are often required after the trim (amputation) labiaplasty.

Sources: en.wikipedia.org

Frequently asked questions

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

What happens to Selank after intranasal dosing?

The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.

How strong is the clinical evidence?

Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.

How should the powder be stored?

Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.

Network